Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
Bringhen S, Milan A, Ferri C, Waesch R, Gay F, Larocca A, Salvini M, Terpos E, Goldschmidt H, Cavo M, Petrucci MT, Ludwig H, Auner HW, Caers J, Gramatzki M, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M (2018)
Publication Type: Journal article, Review article
Publication year: 2018
Journal
Book Volume: 103
Pages Range: 1422-1432
Journal Issue: 9
DOI: 10.3324/haematol.2018.191288
Abstract
Cardiovascular disease in patients with multiple myeloma may derive from factors unrelated to the disease (age, diabetes, dyslipidemia, obesity, prior cardiovascular diseases), related to the disease (cardiac AL-amyloidosis, hyperviscosity, high-output failure, arteriovenous shunting, anemia, renal dysfunction) and/or related to anti-myeloma treatment (anthracyclines, corticosteroids, alkylating agents, immunomodulatory drugs, proteasome inhibitors). Good knowledge of cardiovascular events, effective dose reductions, prevention and management of early and late cardiovascular side effects of chemotherapeutic agents are essential in current clinical practice. Myeloma experts are obliged to carefully balance the efficacy and toxicity of drugs for each individual patient. This review summarizes current data and novel insights into cardiovascular adverse events of today's anti-myeloma treatment, focusing on carfilzomib, as a starting point for developing consensus recommendations on preventing and managing cardiovascular side effects in patients with multiple myeloma.
Involved external institutions
University of Turin / Università degli Studi di Torino (UNITO)
Italy (IT)
University of L'Aquila / Università degli Studi dell'Aquila
Italy (IT)
Albert-Ludwigs-Universität Freiburg
Germany (DE)
National and Kapodistrian University of Athens
Greece (GR)
Universitätsklinikum Heidelberg
Germany (DE)
University of Bologna / Università di Bologna
Italy (IT)
Università degli studi "La Sapienza"
Italy (IT)
Wilhelminenspital
Austria (AT)
Imperial College London / The Imperial College of Science, Technology and Medicine
United Kingdom (GB)
Christian-Albrechts-Universität zu Kiel
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Erasmus University Medical Center (MC)
Netherlands (NL)
Italy (IT)
University of L'Aquila / Università degli Studi dell'Aquila
Italy (IT)
Albert-Ludwigs-Universität Freiburg
Germany (DE)
National and Kapodistrian University of Athens
Greece (GR)
Universitätsklinikum Heidelberg
Germany (DE)
University of Bologna / Università di Bologna
Italy (IT)
Università degli studi "La Sapienza"
Italy (IT)
Wilhelminenspital
Austria (AT)
Imperial College London / The Imperial College of Science, Technology and Medicine
United Kingdom (GB)
Christian-Albrechts-Universität zu Kiel
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Erasmus University Medical Center (MC)
Netherlands (NL)
How to cite
APA:
Bringhen, S., Milan, A., Ferri, C., Waesch, R., Gay, F., Larocca, A.,... Engelhardt, M. (2018). Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica, 103(9), 1422-1432. https://doi.org/10.3324/haematol.2018.191288
MLA:
Bringhen, Sara, et al. "Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)." Haematologica 103.9 (2018): 1422-1432.
BibTeX: Download